News & Perspective

Apr 24, 2006

Apr 24, 2006

Study cites gaps in Europe's flu pandemic plans

(CIDRAP News) – European countries' plans for coping with an influenza pandemic are generally good but have a number of gaps, including a lack of detail on distribution of drugs and supplies, according to an analysis published last week by The Lancet.

Jun 09, 2006

Jun 09, 2006

Officials call Asia-Pacific pandemic drill a success

(CIDRAP News) – Australian officials who coordinated an exercise Jun 7 and 8 on pandemic influenza response among Asia-Pacific nations called the drill a success, according to an Agence France-Presse (AFP) story today.

Jun 28, 2006

Jun 28, 2006

Report: Flu pandemic could cut economic output 3-9%

(CIDRAP News) – An influenza pandemic would reduce the gross domestic products of the world's major economies by amounts ranging from 9% in China to 3% in Canada, according to a recent report by the Australian Bureau of Agricultural and Resource Economics (ABARE).

Jul 18, 2006

Jul 18, 2006

Novartis to build US cell-based flu vaccine plant

(CIDRAP News) – Novartis, the Swiss-based drug manufacturer, today announced plans to build what it says will be the first US plant to make cell-culture-based influenza vaccines.

The facility will be built in Holly Springs, N.C., at a total cost of about $600 million, the company said in a news release. It will be able to produce about 50 million doses of seasonal trivalent (three-strain) flu vaccine annually.

Sep 19, 2006

Sep 19, 2006

Sanofi tests H7N1 flu vaccine for pandemic readiness

(CIDRAP News) – Sanofi Pasteur today announced the start of the first clinical trial of an H7N1 influenza vaccine, intended to guard against the threat of a pandemic caused by H7 strains of avian influenza.

Current concern about a flu pandemic focuses mainly on the H5N1 avian flu virus, which has infected at least 247 people and killed 144. But H7 avian flu viruses have caused a number of mild illness cases and one death in the past 3 years.

Apr 27, 2007

Apr 27, 2007

Panel supports EU approval of cell-based flu vaccine

(CIDRAP News) – A committee that reviews medical product applications for the European Union (EU) yesterday recommended approval of a cell-based seasonal influenza vaccine made by Novartis, improving the company's chance of becoming the first to market a flu vaccine grown in cell culture instead of in eggs.

May 09, 2007

May 09, 2007

EU approves Novartis's 'mock-up' pandemic vaccine

(CIDRAP News) – The European Union (EU) this week approved a "mock-up" influenza vaccine made by Novartis to permit a faster start on vaccine production in the event of a flu pandemic.

Jun 13, 2007

Jun 13, 2007

EU approves Novartis's cell-based flu vaccine

(CIDRAP News) – The European Union (EU) has approved Novartis's seasonal influenza vaccine, Optaflu, putting the Swiss company in a position to become the first to market a flu vaccine grown in cell culture rather than eggs.

Jun 19, 2007

Jun 19, 2007

FLU CONFERENCE COVERAGE Virus ownership claims could disrupt flu vaccine system

– TORONTO (CIDRAP News) – The continuing debate over developing countries' ability to afford pandemic-influenza vaccines has produced a disturbing complication: the possibility that Indonesia and other countries affected by H5N1 avian flu will assert legal ownership of the viral isolates on which the vaccines would be based.

Oct 29, 2007

Oct 29, 2007

THE PANDEMIC VACCINE PUZZLE Part 3: H5N1 poses major immunologic challenges

Editor's note: This is the third in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Pages

Sort Results By:

 Sort Results By:

Narrow results by:

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by

  Become an underwriter»